The effects of naltrexone maintenance on the response to yohimbine in healthy volunteers

Biological Psychiatry

Volumn 45, Issue 12, 1999, Pages 1636-1645

  Rosen, Marc I ^a   Kosten, Thomas R ^a   Kreek, Mary Jeanne ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Cortisol; Locus coeruleus; Naltrexone; Noradrenergic; Stress; Yohimbine

Indexed keywords

NALTREXONE; YOHIMBINE;

ADULT; ANXIETY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; LOCUS CERULEUS; NEUROMODULATION; NORADRENERGIC SYSTEM; NORMAL HUMAN; PENIS ERECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STRESS;

ADULT; APHRODISIACS; DOUBLE-BLIND METHOD; DRUG HYPERSENSITIVITY; FEMALE; HEALTH STATUS; HUMANS; HYDROCORTISONE; INJECTIONS, INTRAVENOUS; MALE; NALTREXONE; NARCOTIC ANTAGONISTS; SEXUAL BEHAVIOR; TIME FACTORS; YOHIMBINE;

EID: 0033564788     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(98)00259-5     Document Type: Article

References (53)

1. Aghajanian G.H. Tolerance of locus coeruleus neurons to morphine and suppression of withdrawal response to clonidine. Nature. 276:1978;186-188.
2. Atkinson R.L. Endocrine and metabolic effects of opiate antagonists. J Clin Psychiatry. 45:(9):1994;20-24.
3. Bardo M.T., Bhatnagar R.K., Gebhart G.F. Chronic naltrexone increases opiate binding in brain and produces super sensitivity to morphine in the locus coeruleus of the rat. Brain Res. 289:1983;223-234.
4. Billingsley M.L., Kubena R.K. The effect of naloxone and picrotoxin on the sedative and anticonflict effects of benzodiazepines. Life Sci. 22:1978;897-906.
5. Bouloux P., Grossman A., Lytras N., Besser G. Evidence for the participation of endogenous opioids in the sympathoadrenal response to hypoglycemia in man. Clin Endocrinol. 22:1985;49-56.
6. 2-adrenergic and opiate receptor blockade Synergistic effects on anxiety in healthy subjects . Arch Gen Psychiatry. 43:1986;1037-1041.
7. Charney D.S., Heninger G.R., Breir A. Noradrenergic function in panic anxiety Effects of yohimbine in healthy subjects and patients with agoraphobia and panic disorder . Arch Gen Psychiatry. 41:1984;751-763.
8. Cohen M.R., Cohen R.M., Pickar D., Weingartner H., Murphy D.L. High dose naloxone infusions in normals. Dose-dependent behavioral, hormonal, and physiological responses. Arch Gen Psychiatry. 40:(6):1983;613-619.
9. Cohen M.R., Cohen R.M., Pickar D., Weingartner H., Murphy D.L., Bunney W.E. Behavioral effects after high dose naloxone administration to normal volunteers. Lancet. 2:1981;1110.
10. Cote T.E., Izenwasser S., Weems H.B. Naltrexone-induced upregulation of mu opioid receptors on 7315c cell and brain membranes Enhancement of opioid efficacy in inhibiting adenylyl cyclase . J Pharmacol Exp Ther. 267:1993;238-244.
11. Crawley J.N., Laverty R.N., Roth R.H. Clonidine reversal of increased norepinephrine metabolite levels during morphine withdrawal. Eur J Pharmacol. 57:1979;247-255.
12. Dai S., Chan M. Effects of naloxone on serum corticosterone and gastric lesions in stressed rats. Pharmacology. 27:1983;180-184.
13. Davidson A.F., Emm T.A., Pieniaszek H.J. Determination of naltrexone and its major metabolite, 6-beta-naltrexol, in human plasma using liquid chromatography with electrochemical detection. J Pharm Biomed Anal. 14:(12):1996;1717-1725.
14. Dingledine R., Iversen L.L., Breuker E. Naloxone as a GABA antagonist Evidence from iontophoretic, receptor binding and convulsant studies . Eur J Pharmacol. 47:1978;19-27.
15. Doxey J.C., Lane A.C., Roach A.G., Virdee N.K. Comparison of the alpha-adrenoreceptor antagonist profiles of idazoxan (RX 781094), yohimbine, rauwolscine, and corynanthine. Naunyn Schmiedebergs Arch Pharmacol. 325:1984;136-144.
16. Egan K.J., Carr J.E., Hunt D.D., Adamson R. Endogenous opiate system and systematic desensitization. J Consult Clin Psychol. 56:(2):1988;287-291.
17. Eisenman A.J., Sloan J.W., Martin W.R., Jasinski D.R., Brooks J.W. Catecholamine and 17-hydroxycorticosteroid excretion during a cycle of morphine dependence in man. J Psychiatric Res. 7:1969;19-28.
18. Ernsberger P., Giuliano R., Willette R.N., Reis D.J. Role of imidazole receptors in the vasodepressor response to clonidine analogs in the rostral ventrolateral medulla. J Pharmacol Exp Ther. 253:1990;408-418.
19. Fudala P.J., Heishman S.J., Henningfeld J.E., Johnson R.E. Human pharmacology and abuse potential of nalmefene. Clin Pharmacol Ther. 49:1991;300-306.
20. Goddard A.W., Woods S.W., Sholomskas D.E., Goodman W.K., Charney D.S., Heninger G.R. Effects of the serotonin reuptake inhibitor fluvoxamine on yohimbine-induced anxiety in panic disorder. Psychiatry Res. 48:1993;119-133.
21. Gurll N.J., Reynolds D.G., Vargish T., Lechner R. Naloxone without transfusion prolongs survival and enhances cardiovascular function in hypovolemic shock. J Pharmacol Exp Ther. 220:1982;621-624.
22. Guthrie S.K., Hariharan M., Grunhaus L.J. Yohimbine bioavailability in humans. Eur J Clin Pharmacol. 39:1990;409-411.
23. 2 adrenergic receptors in rat brain. Nature. 291:1981;493-495.
24. Hockings G.I., Grice J.E., Wark W.K., Walters M.M., Jensen G.R., Jackson R.V. Hypersensitivity of the hypothalamic-pituitary adrenal axis to naloxone in post-traumatic stress disorder. Bio Psychiatry. 33:1993;585-593.
25. Hollister L.E., Johnson K., Boukhabza D., Gillespie H.K. Aversive effects of naltrexone in subjects not dependent on opiates. Drug Alcohol Depend. 8:1981;37-41.
26. Jordan C., Lehane J.R., Jones J.G. Respiratory depression following diazepam Reversal with high-dose naloxone . Anesthesiology. 53:(4):1980;293-298.
27. Karoum F., Wyatt R.J., Majchrowicz E. Brain concentrations of biogenic-amine metabolites in acutely treated and ethanol dependent rats. Br J Pharmacol. 56:1976;403-411.
28. Kohno Y., Tanaka M., Hoaki Y., Ida Y., Nagasaki N. Differential modification by opioid agents of acutely enhanced adrenaline release in discrete brain regions. Eur J Pharmacol. 92:1983;265-268.
29. Konishi S., Tsuanao A., Otsuka M. Enkephalin as a transmitter for presynaptic inhibition in sympathetic ganglia. Nature. 294:1981;80-82.
30. Kosten T.R., Kreek M.J., Ragunath J., Kleber H.D. Cortisol levels during chronic naltrexone maintenance treatment in ex-opiate addicts. Biol Psychiatry. 21:1986;217-220.
31. Kosten T., Silverman D.G., Fleming J., et al. Intravenous cocaine challenges during naltrexone maintenance A preliminary study . Biol Psychiatry. 32:1992;543-548.
32. Kreek MJ (1992): Effects of opiates, opioid antagonists, and cocaine on the endogenous opioid system: Clinical and laboratory studies. In: L.S. Harris, editor. Problems of Drug Dependence, 1991: Proceedings of the 53rd Annual Scientific Meeting. The Committee on Problems of Drug Dependence, Inc., National Institute on Drug Abuse Monograph. Washington, DC: Supt of Docs, US Govt Printing Office, DHHS Pub. No. (ADM) 92-1888. 119:44-48.
33. Kreek MJ, Schneider BS, Raghunath J, Plevy S (1984): Prolonged (24 hour) infusion of the opioid antagonist naloxone does not significantly alter plasma levels of cortisol and ACTH in humans. Abstracts of the Seventh International Congress of Endocrinology, Excerpta Medica International Congress Series 652, Amsterdam Oxford-Princeton: 845, July 1984.
34. Krystal J.H., McDougle C.J., Woods S.W., Price L.H., Heninger G.R., Charney D.S. Dose-response relationship for oral idazoxan effects in healthy human subjects comparison with oral yohimbine . Psychopharmacology. 108:1992;313-319.
35. Laverty R., Roth R.H. Clonidine reverses the increased norepinephrine turnover during morphine withdrawal in rats. Brain Res. 182:1980;482-485.
36. Lewis J.W., Cannon J.T., Liebeskind J.C. Opioid and non-opioid mechanisms of stress analgesia. Science. 208:1980;623-625.
37. Luby ED, Marrazzi MA (1987): A panic attack precipitated by opiate blockade - a case study. J Clin Psychopharmacol 7(5):361-326.
38. Martin W.R., Jasinski D.R. Physiological parameters of morphine dependence in man-tolerance, early abstinence, protracted abstinence. J Psychiat Res. 7:1969;9-17.
39. McCubbin J.A., Surwitt R.S., Kuhn C.M., Cochrane C., Feinglos M.N. Naltrexone potentiates glycemic responses during stress and epinephrine challenge in genetically obese mice. Psychosom Med. 51:1989;441-448.
40. McDougle C.J., Black J.E., Malison R.T., et al. Noradrenergic dysregulation during discontinuation of cocaine use in addicts. Arch Gen Psychiatry. 51:1994;713-719.
41. McDougle C.J., Krystal J.H., Price L.H., Heninger G.R., Charney D.S. Noradrenergic response to acute ethanol administration in healthy subjects Comparison with intravenous yohimbine . Psychopharmacology. 118:1995;127-135.
42. Merluzzi T.V., Taylor C.B., Boltwood M., Gotestam K.G. Opioid antagonist impedes exposure. J Consult Clin Psychol. 59:1991;425-430.
43. 2-adrenergic receptors Implications for depression . Critical reviews in Neurobiology. 9:(1):1994;29-66.
44. Rosen M.I., McMahon T.J., Margolin A., et al. Reliability of sequential naloxone challenge tests. Am J Drug Alcohol Abuse. 21:(4):1995;453-467.
45. Sawynok J., Pinsky C., Labella F.S. Mini-review of the specificity of naloxone as an opiate antagonist. Life Sci. 25:1979;1621-1632.
46. Scatton B., Zivkivic B., Dedek J. Antidopaminergic properties of yohimbine. J Pharmacol Exp Ther. 215:1980;494-499.
47. 3H]noradrenaline release from rat cerebral cortex slices by different mechanisms . Eur J Pharmacol. 79:1982;329-332.
48. Schluger J, Bodner G, Gunduz M, Ho A, Kreek MJ (in press): Abnormal metyrapone tests during cocaine abstinence. In: Harris LS, editor. Problems of Drug Dependence, 1997; Proceedings of the 59th Annual Scientific Meeting of the College on Problems of Drug Dependence. National Institute on Drug Abuse Research Monograph Series, Washington, DC,: Supt of Docs, US Govt Printing Office.
49. Southwick S.M., Krystal J.H., Morgan A., et al. Abnormal noradrenergic function in post traumatic stress disorder. Arch Gen Psychiatry. 50:1993;266-274.
50. Starke E. Regulation of noradrenaline release by presynaptic receptor systems. Biochem Pharmacol. 1:1977;77.
51. Swift R.M., Whelihan W., Kuznetsov O., Buongiorno G., Hsuing H. Naltrexone-induced alterations in human ethanol intoxication. Am J Psychiatry. 151:1994;1463-1467.
52. Unterwald E.M., Rubenfeld J.M., Imai Y., Wang J.B., Uhl G.R., Kreek M.J. Chronic opioid antagonist administration upregulates mu opioid receptor binding without altering mu opioid receptor mRNA levels. Mol Brain Res. 33:1995;351-355.
53. Winter J.C., Rabin R.A. Yohimbine as a serotonergic agent Evidence from receptor binding and drug discrimination . J Pharmacol Exp Ther. 263:1992;682-689.